With the advent of checkpoint inhibitors, including PD‐1 and PD‐L1 inhibitors, there has been a paradigm shift in immunotherapy from targeting the cancer cell to targeting tumor‐mediated immune tolerance 44. This evidence concerns the gene PDCD1 and neoplasm.